Spexis sells antibiotics programme to Basilea
Spexis AG (Alschwil) has entered into an asset purchase agreement with Basilea Pharmaceutica Ltd. Under the agreement Basilea will acquire a...
Novartis AG to buy immunology specialist Calypso Biotech BV
Upon closure, the US$425m take-over of the Amsterdam-headquartered Calypso Biotech NV, would give Novartis AG full commercialisation rights to...
EU parliament backs deregulation of New Genome Techniques
With the MEPs' approval of the amendments to the European Commission's draft legislation, the way is now clear for a regulation that distinguishes...
Production process for cell-based coffee published
Given the high environmental costs of producing 10 million tonnes of coffee per year, scientists have been considering biotechnological production...
LimmaTech Biologics acquires licence option for AbVacc vaccine LBT-SA7
Under the agreement, Schlieren-based LimmaTech Biologics AG receives the exclusive rights from Abbvacc Inc, a recent spin-out from Integrated...
miRNA specialist Resalis Therapeutics Srl raises €10m in Series A financing
Existing investors including Claris Ventures and angel investors participated in the financing The proceeds will be used to initiate and complete the...
Germany blocks deregulation of NGT breeds
The Spanish EU Council Presidency wanted to speed up a decision on the new regulation that foresees to allow a faster market approval of breeds made...